title: Structural and functional characterization of the trifunctional antibody catumaxomab.
abstract: The Triomab family of trifunctional, bispecific antibodies that maintain an IgG-like shape are novel tumor targeting agents. These chimeras consist of two half antibodies, each with one light and one heavy chain, that originate from parental mouse IgG2a and rat IgG2b isotypes. This combination allows cost-effective biopharmaceutical manufacturing at an industrial scale since this specific mouse/rat isotype combination favors matching of corresponding antibody halves during production by means of quadroma technology. Whereas every Triomab family member is composed of an anti-CD3 rat IgG2b half antibody for T cell recognition, the antigen binding site presented by the mouse IgG2a isotype is exchangeable. Several Triomab antibodies have been generated that bind to tumor-associated antigens, e.g., EpCAM (catumaxomab), HER2/neu (ertumaxomab), CD20 (FBTA05), gangliosides GD2/GD3 (Ektomun), on appropriate tumor target cells associated with carcinomas, lymphomas or melanomas. Catumaxomab (Removab) was launched in Europe for treatment of malignant ascites in April 2009. Here, we report the structural and functional characterization of this product. Mass spectrometry revealed an intact mass of 150511 Dalton (Da) and 23717 Da, 24716 Da, 51957 Da and 52019 Da of the reduced and alkylated rat light chain, mouse light chain, rat heavy chain, mouse heavy chain chains, respectively. The observed masses were in agreement with the expected masses based on the amino acid sequence obtained from cDNA sequencing. The glycosylation profile was similar to other human IgG consisting of biantennary oligosaccharides with different numbers of terminal galactose. CD spectroscopy showed mainly beta-sheets secondary structure that is typical for IgG antibodies. Binding measurement revealed the unique trifunctional features of catumaxomab. Other analytical tools were used to evaluate characteristics of catumaxomab preparations, including the presence of isoforms and aggregates.
authors.affiliation: TRION Pharma GmbH, Munich, Germany. dirk.chelius@trionpharma.de
authors.forename: Dirk
authors.initials: D
authors.lastname: Chelius
authors.forename: Peter
authors.initials: P
authors.lastname: Ruf
authors.forename: Patrick
authors.initials: P
authors.lastname: Gruber
authors.forename: Matthias
authors.initials: M
authors.lastname: Plöscher
authors.forename: Reinhard
authors.initials: R
authors.lastname: Liedtke
authors.forename: Eva
authors.initials: E
authors.lastname: Gansberger
authors.forename: Juergen
authors.initials: J
authors.lastname: Hess
authors.forename: Michael
authors.initials: M
authors.lastname: Wasiliu
authors.forename: Horst
authors.initials: H
authors.lastname: Lindhofer
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry* / Q000276:immunology*; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000737:chemistry; D007147:Immunoglobulin Light Chains / Q000737:chemistry; D051379:Mice; D008970:Molecular Weight; D051381:Rats
chemical_list: D018033:Antibodies, Bispecific; D007143:Immunoglobulin Heavy Chains; D007147:Immunoglobulin Light Chains; C522419:catumaxomab